Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of General Internal Medicine
Published in: Journal of General Internal Medicine 9/2011

01-09-2011 | Reviews

Psoriasis and Vascular Disease—Risk Factors and Outcomes: A Systematic Review of the Literature

Authors: Rita V. Patel, MD, Michael L. Shelling, MD, Srdjan Prodanovich, MD, Daniel G. Federman, MD, Robert S. Kirsner, MD, PhD

Published in: Journal of General Internal Medicine | Issue 9/2011

Login to get access

Abstract

Background

Psoriasis afflicts 2-3% of the world’s population. Affected patients commonly have risk factors for cardiovascular disease (CVD). In addition, psoriasis is independently associated with CVD and mortality.

Purpose

To determine which CVD risk factors are associated with psoriasis independent of confounders, whether psoriasis is associated with CVD independent of CVD risk factors, and whether there is increased mortality among patients with psoriasis.

Data Sources

MEDLINE, Embase, and Cochrane Collaborations from inception through October 2009. We reviewed bibliographies of retrieved articles for additional references.

Study Selection

Cross-sectional, cohort-based, case-control, and randomized controlled trials which involved patients with psoriasis.

Data Extraction

Two investigators independently reviewed studies and resolved any discrepancies by consensus.

Data Synthesis

Of the 2,303 articles identified by literature search, 90 studies met inclusion criteria for this review; 15 were cohort-based studies, 45 were case-control, and 30 were cross-sectional.

Limitations

The quality of evidence was limited by study heterogeneity and lack of large scale prospective studies with long-term follow-up.

Conclusions

Patients with psoriasis demonstrate a higher prevalence of cardiovascular risk factors and appear to be at increased risk for ischemic heart disease, cerebrovascular disease, and peripheral arterial disease. This increase in vascular disease may be independent of shared risk factors and may contribute to the increase in all-cause mortality. Future research should aim to more confidently distinguish between a true causal relationship or merely an association resulting from multiple shared risk factors. Physicians should screen for and aggressively treat modifiable risk factors for CVD in patients with psoriasis.
Literature
1.
2.
Esposito M, Saraceno R, Guinta A, Maccarone M, Chimenti S. An Italian study on psoriasis and depression. Dermatology. 2006;212(2):123–7.PubMedCrossRef
3.
Russo PA, Ilchef R, Cooper AJ. Psychiatric morbidity in psoriasis: a review. Australas J Dermatol. 2004;45(3):155–9.PubMedCrossRef
4.
Kimball AB, Jacobson C, Weiss C, Vreeland MG, Wu Y. The psychosocial burden of psoriasis. Am J Clin Dermatol. 2005;6(6):383–92.PubMedCrossRef
5.
Kremers H, McEvoy MT, Dann FJ, Gabriel SE. Heart disease in psoriasis. J Am Acad Dermatol. 2007;57(2):347–54.PubMedCrossRef
6.
Svenungsson E, Jensen-Urstad K, Heimbürger M, Silveira A, Hamsten A, de Faire U, et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation. 2001;104(16):1887–93.PubMedCrossRef
7.
Wallberg-Jonsson S, Ohman ML, Dahlqvist SR. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol. 1997;24(3):445–51.PubMed
8.
9.
Shapiro J, Cohen AD, David M, Hodak E, Chodik G, Viner A, et al. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: A case-control study. J Am Acad Dermatol. 2007;56(4):629–34.PubMedCrossRef
10.
Gonzalez-Juanatey C, Lorca J, Mirando-Filloy JA, Amigo-Diaz E, Testa A, Garcia-Porrua C, et al. Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic arthrosclerosis risk factors. Arthritis Rheum. 2007;57(2):287–93.PubMedCrossRef
11.
Gonzalez-Juanatey C, Lorca J, Amigo-Diaz E, Dierssen T, Javier M, Gonzalez-Gay M. High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinical evident cardiovascular disease or classic arthrosclerosis risk factors. Arthritis Rheum. 2007;57(6):1074–80.PubMedCrossRef
12.
Balci D, Balci A, Karazincir S, Ucar E, Iyigun U, Yalcin F, et al. Increased carotid artery intima-media thickness and impaired endothelial function in psoriasis. J Eur Acad Dermatol Venereol. 2009;23(1):1–6.PubMedCrossRef
13.
Kimhi O, Caspi D, Bornstein NM, Maharshak N, Gur A, Arbel Y, et al. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum. 2007;36(4):203–9.PubMedCrossRef
14.
Yalcin H, Balci DD, Ucar E, Ozcelik N, Tasci C, Seyfeli E, et al. Myocardial perfusion is preserved in patients with psoriasis without clinically evident cardiovascular disease. J Eur Acad Dermatol Venereol. 2009;23(7):798–802.PubMedCrossRef
15.
Uyanik BS, Ari Z, Onur E, Gündüz K, Tanülkü S, Durkan K. Serum lipids and apolipoproteins in patients with psoriasis. Chin Chem Lab Med. 2002;40(1):65–8.CrossRef
16.
Kaye JA, Li L, Jick SS. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol. 2008;159(4):895–902.PubMedCrossRef
17.
Mallbris L, Granath F, Hamsten A, Ståhle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol. 2006;54(4):614–21.PubMedCrossRef
18.
Piskin S, Gurkok F, Ekuklu G, Senol M. Serum lipid levels in psoriasis. Yonsei Med J. 2003;44(1):24–6.PubMed
19.
Reynoso-von Drateln C, Martínez-Abundis E, Balcázar-Muñoz BR, Bustos-Saldaña R, González-Ortiz M. Lipid profile, insulin secretion, and insulin sensitivity in psoriasis. J Am Acad Dermatol. 2003;48(6):822–5.
20.
Dreiher J, Weitzman D, Davidovici B, Shapiro J, Cohen AD. Psoriasis and dyslipidaemia: a population-based study. Acta Derm Venereol. 2008;88(6):561–5.PubMed
21.
Pietrzak A, Kadzielewski J, Janowski K, Roliński J, Krasowska D, Chodorowska G, et al. Lipoprotein (a) in patients with psoriasis: associations with lipid profiles and disease severity. Int J Dermatol. 2009;48(4):379–87.PubMedCrossRef
22.
Akhyani M, Ehsani AH, Robati RM, Robati AM. The lipid profile in psoriasis: a controlled study. J Eur Acad Dermatol Venereol. 2007;21(10):1330–2.PubMedCrossRef
23.
Jones SM, Harris PD, Lloyd J, Stirling CA, Reckless JP, McHugh NJ. Lipoproteins and their subfractions in psoriatic arthritis: identification of an atherogenic profile with active joint disease. Ann Rheum Dis. 2000;59(11):904–9.PubMedCrossRef
24.
Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha A, Teixeira F. Dyslipidemia and oxidative stress in mild and severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta. 2001;303(1–2):33–9.PubMedCrossRef
25.
Han C, Robinson DW, Hackett MV, Paramore LC, Fraeman KH, Bala MV. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol. 2006;33(11):2167–72.PubMed
26.
Kimball AB, Robinson D, Wu Y, Guzzo C, Yeilding N, Paramore C, et al. Cardiovascular disease and risk factors among psoriasis patients in two US healthcare databases, 2001–2002. Dermatology. 2008;217(1):27–37.PubMedCrossRef
27.
Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55(5):829–35.PubMedCrossRef
28.
Vanizor Kural B, Orem A, Cimsit G, Uydu HA, Yanid YE, Alver A. Plasma homocysteine and its relationships with atherothrombotic markers in psoriatic patients. Clin Chim Acta. 2003;332(1–2):23–30.PubMedCrossRef
29.
Malerba M, Gisondi P, Radaeli A, Sala R, Calzavara Pinton PG, Girlomoni G. Plasma homocysteine and folate levels in patients with chronic plaque type psoriasis. Br J Dermatol. 2006;155(6):1165–9.PubMedCrossRef
30.
Cakmak SK, Gül U, Kiliç C, Gönül M, Soylu S, Kiliç A. Homocysteine, vitamin B12 and folic acid levels in psoriasis patients. J Eur Acad Dermatol Venereol. 2009;23(3):300–3.PubMedCrossRef
31.
Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. 2001;103(13):1813–8.PubMed
32.
Ohtsuka T. The relation between high-sensitivity C-reactive protein and maximum body mass index in patients with psoriasis. Br J Dermatol. 2008;158(5):1141–3.PubMedCrossRef
33.
Biyik I, Narin A, Bozok MA, Ergene O. Echocardiographic and clinical abnormalities in patients with psoriasis. J Intl Med Res. 2006;34(6):632–9.
34.
Qureshi AA, Choi HK, Setty AR, Curhan GC. Psoriasis and the risk of diabetes and hypertension. Arch Dermatol. 2009;145(4):379–82.PubMedCrossRef
35.
Gerdes A, Zahl VA, Knopf H, Weichenthal M, Mrowietz U. Comedication related to comorbidities: a study in 1203 hospitalized patients with severe psoriasis. Br J Dermatol. 2008;159(5):1116–23.PubMed
36.
Ho VC. The use of cyclosporine in psoriasis: a clinical review. Br J Dermatol. 2004;150(suppl 67):1–10.PubMedCrossRef
37.
Reeds RE Jr, Fusaro RM, Fisher I. Psoriasis vulgaris I: a clinical survey of the association with diabetes mellitus. Arch Dermatol. 1964;89:205–8.PubMedCrossRef
38.
Brauchli YB, Jick SS, Meier CR. Psoriasis and the risk of incident diabetes mellitus: a population-based study. Br J Dermatol. 2008;159(6):1331–7.PubMedCrossRef
39.
Wu Y, Mills D, Bala M. Psoriasis: cardiovascular risk factors and other disease comorbidities. J Drug Dermatol. 2008;7(4):373–7.
40.
Herron MD, Hinckley M, Hoffman MS, Papenfuss J, Hansen CB, Callis KP, et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol. 2005;141(12):1527–34.PubMedCrossRef
41.
Wolk K, Mallbris L, Larsson P, Rosenblad A, Vingård E, Ståhle M. Excessive body weight and smoking associates with a high risk of onset of plaque psoriasis. Acta Derm Venereol. 2009;89(5):492–7.PubMedCrossRef
42.
Johnston A, Arnadottir S, Gudjonnson JE, Aphale A, Sigmarsdottir AA, Gunnarsson SI, et al. Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation. Br J Dermatol. 2008;159(2):342–50.PubMedCrossRef
43.
Cerman AA, Bozkurt S, Sav A, Tulunay A, Elbaşi MO, Ergun T. Serum leptin levels, skin leptin, and leptin receptor expression in psoriasis. Br J Dermatol. 2008;159(4):820–6.PubMedCrossRef
44.
Chen YJ, Wu CY, Shen JL, Chu SY, Chen CK, Chang YT, et al. Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome. Arch Dermatol. 2008;144(12):1571–5.PubMedCrossRef
45.
Jin Y, Zhang F, Yang S, Kong Y, Xiao F, Hou Y, et al. Combined effects of HLA-Cw6, body mass index, and waist-hip ratio on psoriasis vulgaris in Chinese Han population. J Dermatol Sci. 2008;52(2):123–9.PubMedCrossRef
46.
Kaur S, Zilmer K, Kairane C, Kals M, Zilmer M. Clear differences in adiponectin and glutathione redox status revealed in obese and normal-weight patients with psoriasis. Br J Dermatol. 2008;159(6):1364–7.PubMedCrossRef
47.
McGowan JW, Pearce DJ, Chen J, Richmond D, Balkrishnan R, Feldman SR. The skinny of psoriasis and obesity. Arch Dermatol. 2005;141(12):1601–2.PubMedCrossRef
48.
Murray ML, Bergstresser PR, Adams-Huet B, Cohen JB. Relationship of psoriasis severity to obesity using same-gender siblings as controls for obesity. Clin Exp Dermatol. 2008;34(2):140–4.PubMedCrossRef
49.
Naldi L, Chatenoud L, Linder D, Belloni Fortina A, Peserico A, Virgili AR, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol. 2005;125(1):61–7.PubMedCrossRef
50.
Wang Y, Chen J, Zhao Y, Geng L, Song F, Chen HD. Psoriasis is associated with increased levels of serum leptin. Br J Dermatol. 2008;158(2):1134–5.PubMedCrossRef
51.
Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital based case-control study. Br J Dermatol. 2007;157(1):68–73.PubMedCrossRef
52.
Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, and risk of psoriasis in women. Arch Intern Med. 2007;167(15):1670–5.PubMedCrossRef
53.
54.
Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol. 2006;298(7):321–8.CrossRef
55.
Cohen AD, Sherf M, Vidavsky L, Vardy DA, Shapiro J, Meyerovitch J. Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology. 2008;216(2):152–5.PubMedCrossRef
56.
Cohen AD, Gilutz H, Henkin Y, Zahger D, Shapiro J, Bonneh DY, et al. Psoriasis and the metabolic syndrome. Acta Dermatol Venereol. 2007;87(6):506–9.CrossRef
57.
Bongiorno MR, Doukaki S, Rizzo D, Aricò M. The prevalence of the obesity in patients with moderate to severe psoriasis in Sicily populations. JEADV 2009; [Epub ahead of print]
58.
Huerta C, Rivero E, Garcia Rodriguez LA. Incidence and risk factors for psoriasis in the general population. Arch Dermatol. 2007;143(12):1559–65.PubMedCrossRef
59.
Naldi L, Peli L, Parazzini F. Association of early-stage psoriasis with smoking and male alcohol consumption: evidence from an Italian case-control study. Arch Dermatol. 1999;135(12):1479–84.PubMedCrossRef
60.
Mills CM, Srivastava ED, Harvey IM, Swift GL, Newcombe RG, Holt PJ, et al. Smoking habits in psoriasis: a case control study. Br J Dermatol. 1992;127(1):18–21.PubMedCrossRef
61.
Naldi L, Parazzini F, Brevi A, Peserico A, Veller Fornasa C, Grosso G, et al. Family history, smoking habits, alcohol consumption and risk of psoriasis. Br J Dermatol. 1992;127(3):212–7.PubMedCrossRef
62.
Wolkenstein P, Revuz J, Roujeau JC, Bonnelye G, Grob JJ, Bastuji-Garin S. Psoriasis in France and associated risk factors: results of a case-control study based on a large community survey. Dermatology. 2009;218(2):103–9.PubMedCrossRef
63.
Davidsson S, Blomqvist K, Molin L, et al. Lifestyle of Nordic people with psoriasis. Intl J Dermatol. 2005;44(5):378–83.CrossRef
64.
Setty AR, Curhan G, Choi HK. Smoking and the Risk of Psoriasis in Women: Nurses’ Health Study II. Am J Med. 2007;120(11):953–9.PubMedCrossRef
65.
Fortes C, Mastroeni S, Leffondre K, et al. Relationship between smoking and clinical severity of psoriasis. Arch Dermatol. 2005;141(12):1580–4.PubMedCrossRef
66.
Jin Y, Yang S, Zhang F, Kong Y, Xiao F, Hou Y, et al. Combined effects of HLA-Cw6 and cigarette smoking in psoriasis vulgaris: A hospital-based case-control study in China. J Eur Acad Dermatol Venereol. 2009;23(2):132–7.PubMedCrossRef
67.
Zhang X, Wang H, Te-shao H, Yang S, Wang F. Frequent use of tobacco and alcohol in Chinese psoriasis patients. Intl J Dermatol. 2002;41(10):659–62.CrossRef
68.
Jankovic S, Raznatovic M, Marinkovic J, Jankovic J, Maksimovic N. Risk factors for psoriasis: a case-control study. J Dermatol. 2009;36(6):328–34.PubMedCrossRef
69.
O’Keefe JAH, Bybee KA, Lavie CJ. Alcohol and cardiovascular health: the razor-sharp double edged sword. J Am Coll Cardiol. 2007;50(11):1019–24.CrossRef
70.
Poikolainen K, Karvonen J, Pukkala E. Excess mortality related to alcohol and smoking among hospital-treated patient with psoriasis. Arch Dermatol. 1999;135(12):1490–3.PubMedCrossRef
71.
McDonald CJ, Calabresi P. Psoriasis and occlusive vascular disease. Br J Dermatol. 1978;99:469–75.PubMedCrossRef
72.
Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735–41.PubMedCrossRef
73.
Gladman DD, Ang M, Su L, Tom BD, Schentag CT, Farewell VT. Cardiovascular morbidity in psoriatic arthritis (PsA). Ann Rheum Dis. 2009;68(7):1131–5.PubMedCrossRef
74.
Brauchli YB, Jick SS, Miret M, Meier CR. Psoriasis and risk of incident myocardial infarction, stroke or transient ischaemic attack: an inception cohort study with a nested case-control analysis. Br J Dermatol. 2009;160(5):1048–56.PubMedCrossRef
75.
Wakkee M, Herings RM, Nijsten T. Psoriasis may not be an independent risk factor for acute ischemic heart disease hospitalizations: results of a large population-based Dutch cohort. J Invest Dermatol. 2009;[Epub ahead of print]
76.
Xiao J, Chen LH, Tu YT, Deng XH, Tao J. Prevalence of myocardial infarction in patients with psoriasis in central China. J Eur Acad Dermatol Venereol. 2009;23(11):1311–5.PubMedCrossRef
77.
Ludwig RJ, Herzog C, Rostock A, Ochsendorf FR, Zollner TM, Thaci D, et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol. 2007;156(2):271–6.PubMedCrossRef
78.
Gonzalez-Juanetey C, Amigo-Diaz E, Miranda-Filloy JA, Testa A, Revuelta J, Garcia Purrua C, et al. Lack of echocardiographic and Doppler abnormalities in psoriatics arthritis patients without clinically evident cardiovascular disease or classic arthrosclerosis risk factors. Semin Arthritis Rheum. 2006;35(5):333–9.CrossRef
79.
Prodanovich S, Kirsner RS, Kravetz JD, Ma F, Martinez L, Federman DG. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol. 2009;145(6):700–3.PubMedCrossRef
80.
Gelfand JM, Dommasch ED, Shin DB, Azfar RS, Kurd SK, Wang X, et al. The risk of stroke in patients with psoriasis. J Invest Dermatol. 2009;129(10):2411–8.PubMedCrossRef
81.
Stern RS, Lange R. Cardiovascular disease, cancer, and cause of death in patients with psoriasis: 10 years prospective experience in a cohort of 1,380 patients. J Invest Dermatol. 1988;91(3):197–201.PubMedCrossRef
82.
Gelfand JM, Troxel AB, Lewis JD, Kurd SK, Shin DB, Wang X, et al. The risk of mortality in patients with psoriasis. Arch Dermatol. 2007;143(12):1493–9.PubMedCrossRef
83.
Mallbris L, Akre O, Granath F, Yin L, Lindelof B, Ekbom A, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol. 2004;19(3):225–30.PubMedCrossRef
84.
Wong K, Gladman DD, Husted J, Long JA. Farewell VT. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum. 1997;40(10):1868–72.PubMedCrossRef
85.
Naldi L, Chatenoud L, Belloni A, Peserico A, Balato N, Virgili AR, et al. Medical history, drug exposure and the risk of psoriasis: Evidence from an Italian case-control study. Dermatology. 2008;216(2):125–30.PubMedCrossRef
86.
Tam LA, Tomlinson B, Chu TT, Li M, Leung YY, Kwok LW, et al. Cardiovascular risk profile of patients with psoriatic arthritis compared to controls- the role of inflammation. Rheumatol. 2008;47(5):718–23.CrossRef
87.
Grzybowski A, Grzybowski G, Druzdz A, Zaba R. Evaluation of glucose, insulin, C-peptide uric acid serum levels in patients with psoriasis. Pol Merkur Lekarski. 2001;11(66):495–8.PubMed
88.
Karabudak O, Ulusoy RE, Erikci AA, Solmazgul E, Dogan B, Harmanyeri Y. Inflammation and hypercoaguable state in adult psoriatic men. Acta Derm Venereol. 2008;88(4):337–40.PubMed
89.
Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha A, Teixeira F. The inflammatory response in mild and severe psoriasis. Br J Dermatol. 2004;150(5):917–28.PubMedCrossRef
90.
Boehncke S, Thaci D, Beschmann H, Ludwig RJ, Ackermann H, Badenhoop K, et al. Psoriasis patients show signs of insulin resistance. Br J Dermatol. 2007;157(6):1249–51.PubMedCrossRef
91.
Cohen AD, Dreiher J, Shapiro Y, Vidavsky L, Vardy DA, Davidovici B, et al. Psoriasis and diabetes: a population-based cross-sectional study. J Eur Acad Dermatol Venereol. 2008;22(5):585–9.PubMedCrossRef
92.
Markuszeski L, Bissinger A, Janusz I, Narbutt J, Jedrzejowska AS, Zalewska A. Heart rate and arrhythmia in patients with psoriasis vulgaris. Arch Med Res. 2007;38(1):64–9.PubMedCrossRef
93.
Shbeeb M, Uramoto KM, Gibson LE, O'Fallon WM, Gabriel SE. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982–1991. J Rheumatol. 2000;27(5):1247–50.PubMed
94.
Gladman DD, Farewell VT, Wong K, Husted J. Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arth Rheum. 1998;41(6):1103–10.CrossRef
95.
Miot HA, Miot LD, Lopes PS, Haddad GR, Marques SA. Association between palmoplantar pustulosis and cigarette smoking in Brazil: a case-control study. J Eur Acad Dermatol Venereol. 2009;23(10):1173–7.PubMedCrossRef
96.
Coimbra S, Oliveira H, Reis F, Belo L, Rocha S, Quintanilha A, et al. Circulating levels of adiponectin, oxidized LDL and C-reactive protein in Portuguese patients with psoriasis vulgaris, according to body mass index, severity and duration of the disease. J Dermatol Sci. 2009;55(3):202–4.PubMedCrossRef
97.
Takahashi H, Tsuji H, Takahashi I, Hashimoto Y, Ishida-Yamamoto A, Iizuka H. Prevalence of obesity/adiposity in Japanese psoriasis patients: adiposity is correlated with the severity of psoriasis. J Dermatol Sci. 2009;55(1):74–6.PubMedCrossRef
98.
Bajaj DR, Mahesar SM, Devrajani BR, Iqbal MP. Lipid profile in patients with psoriasis presenting at Liaquat University Hospital Hyderabad. J Pak Med Assoc. 2009;59(8):512–5.PubMed
99.
Poikolainen K, Reunala T, Karvonen J, Lauharanta J, Kärkkäinen P. Alcohol intake: a risk factor for psoriasis in young and middle aged men? BMJ. 1990;300(6727):780–3.PubMedCrossRef
100.
Poikolainen K, Reunala T, Karvonen J. Smoking, alcohol and life events related to psoriasis among women. Br J Dermatol. 1994;130(4):473–7.PubMedCrossRef
101.
Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol. 1995;32(6):982–6.PubMedCrossRef
102.
Lindegard B. Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatologica. 1986;172:298–304.PubMedCrossRef
103.
Ridker PM. High-sensitivity C-reactive protein and cardiovascular risk: Rationale for screening and primary prevention. Am J Cardiol. 2003;92(suppl):17K–22K.PubMedCrossRef
104.
Wolfe F, Freundlich B, Straus WL. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol. 2003;30(1):36–40.PubMed
105.
Rhew EY, Ramsey-Goldman R. Premature atherosclerotic disease in systemic lupus erythematosus–role of inflammatory mechanisms. Autoimmun Rev. 2006;5(2):101–5.PubMedCrossRef
106.
Prodanovich S, Shelling ML, Federman DG, Kirsner RS. Cytokine milieu in psoriasis and cardiovascular disease may explain the epidemiological findings relating these 2 diseases. Arch Dermatol. 2008;144(11):1518–9.PubMedCrossRef
Metadata
Title
Psoriasis and Vascular Disease—Risk Factors and Outcomes: A Systematic Review of the Literature
Authors
Rita V. Patel, MD
Michael L. Shelling, MD
Srdjan Prodanovich, MD
Daniel G. Federman, MD
Robert S. Kirsner, MD, PhD
Publication date
01-09-2011
Publisher
Springer-Verlag
Published in
Journal of General Internal Medicine / Issue 9/2011
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-011-1698-5

Other articles of this Issue 9/2011

Journal of General Internal Medicine 9/2011 Go to the issue

Original Research

Food Insecurity is Associated with Poor Virologic Response among HIV-Infected Patients Receiving Antiretroviral Medications

Reviews

Skin Cancer Education for Primary Care Physicians: A Systematic Review of Published Evaluated Interventions

Original Research

Relationship Between Literacy, Knowledge, Self-Care Behaviors, and Heart Failure-Related Quality of Life Among Patients With Heart Failure

Editorials

Safe, High Quality Care Around the Clock: What will it Take to Get us There?

Original Research

The Revolving Door of Resident Continuity Practice: Identifying Gaps in Transitions of Care

Innovation and Improvement: Improvement Happens

Improvement Happens: an Interview with Furman McDonald, MD MPH
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits